Abstract: The invention is related to a formulation comprising of a polyclonal IgY antibodies of SARS CoV2-and a pharmaceutical acceptable carrier, wherein the polyclonal IgY antibodies is in the range of 50- 200 mg (w/v) and wherein the polyclonal IgY antibodies is a lyophilised powder. The formulation is one of nasal spray or a mouth gargle to be used as a prophylaxis and therapeutic formulation against COVID 19. This invention also includes formulation of IgY as enteric coated tablet to neutralize the effect of virus in the intestinal tract. The virus neutralization titer of the formulation is in the range of 1: 3200 - 1: 51200. The polyclonal IgY antibodies neutralizes the SARS CoV 2 virus.
DESC:PLEASE SEE THE ATTACHMENT ,CLAIMS:PLEASE SEE THE ATTACHMENT
| # | Name | Date |
|---|---|---|
| 1 | 202041015027-STATEMENT OF UNDERTAKING (FORM 3) [05-04-2020(online)].pdf | 2020-04-05 |
| 2 | 202041015027-PROVISIONAL SPECIFICATION [05-04-2020(online)].pdf | 2020-04-05 |
| 3 | 202041015027-FORM FOR STARTUP [05-04-2020(online)].pdf | 2020-04-05 |
| 4 | 202041015027-FORM FOR SMALL ENTITY(FORM-28) [05-04-2020(online)].pdf | 2020-04-05 |
| 5 | 202041015027-FORM 1 [05-04-2020(online)].pdf | 2020-04-05 |
| 6 | 202041015027-EVIDENCE FOR REGISTRATION UNDER SSI(FORM-28) [05-04-2020(online)].pdf | 2020-04-05 |
| 7 | 202041015027-DECLARATION OF INVENTORSHIP (FORM 5) [05-04-2020(online)].pdf | 2020-04-05 |
| 8 | 202041015027-Proof of Right [06-04-2020(online)].pdf | 2020-04-06 |
| 9 | 202041015027-FORM-26 [11-05-2020(online)].pdf | 2020-05-11 |
| 10 | 202041015027-PostDating-(31-03-2021)-(E-6-85-2021-CHE).pdf | 2021-03-31 |
| 11 | 202041015027-APPLICATIONFORPOSTDATING [31-03-2021(online)].pdf | 2021-03-31 |
| 12 | 202041015027-DRAWING [03-06-2021(online)].pdf | 2021-06-03 |
| 13 | 202041015027-CORRESPONDENCE-OTHERS [03-06-2021(online)].pdf | 2021-06-03 |
| 14 | 202041015027-COMPLETE SPECIFICATION [03-06-2021(online)].pdf | 2021-06-03 |